Jenburkt Pharmaceuticals
Healthcare
JENBURPH NSE
₹936.25 +42.30 (+4.73%)
- P/E
- 12.59
Close 4 Nov 2026 ₹936.25 −280.50 −23.1% 1Y
Start ₹1,216.75
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 27.00%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹74.39
- Book Value
- ₹446.47
- Market Cap
- —
- P/E (TTM)
- 12.59
- P/B
- 2.10
- ROE
- 20.20%
- Dividend Yield
- 2.32%
- EBITDA
- ₹54.00 Cr
- 52W High
- ₹1,317.00
- 52W Low
- ₹845.00
- Day Range
- ₹916.10 – ₹942.90
- Volume
- 798
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Jenburkt Pharmaceuticals (this company) | ₹936.25 | 12.59 | ₹412 Cr | 2.10 | 2.32% | 20.20% | 27.00% | ₹169 Cr | ₹33 Cr |
| Median 8 companies | ₹1,587.70 | 37.20 | ₹1,25,337 Cr | 4.57 | 0.70% | 17.40% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
61 Good
Data confidence 100/100
Category scores
- Quality
- 69
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 71
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 50
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 90
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 30
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 48
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 25.7%
Weaknesses
1- The company has delivered a poor sales growth of 9.08% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 5 | 6 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Neutral
Bearish
2
Neutral
5
Bullish
2
Overall
Bearish
Bearish
8
Neutral
5
Bullish
6
Moving Averages
Strong Bearish
Bearish
6
Neutral
0
Bullish
4
Key readings
- RSI (14)
- 56.79
- Neutral
- MACD (12,26,9)
- −18.36
- Bullish
- SMA (50)
- 955.54
- Bearish
- SMA (200)
- 1,047.49
- Bearish
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +6.04% |
|---|---|
| 5Y | +9.17% |
| 3Y | +7.25% |
| 1Y | +11.18% |
| TTM | +9.07% |
Net profit
| 10Y | +12.27% |
|---|---|
| 5Y | +16.95% |
| 3Y | +11.87% |
| 1Y | +9.38% |
| TTM | +1.20% |
Operating cash flow
| 10Y | +12.93% |
|---|---|
| 5Y | +7.28% |
| 3Y | +16.67% |
| 1Y | −3.57% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +9.02 pp |
|---|---|
| 5Y | +7.69 pp |
| 3Y | +4.14 pp |
| 1Y | −0.28 pp |
| TTM | −1.71 pp |
Revenue by year
| Mar 2017 | ₹103 Cr |
|---|---|
| Mar 2018 | ₹115 Cr |
| Mar 2019 | ₹123 Cr |
| Mar 2020 | ₹119 Cr |
| Mar 2021 | ₹109 Cr |
| Mar 2022 | ₹124 Cr |
| Mar 2023 | ₹137 Cr |
| Mar 2024 | ₹142 Cr |
| Mar 2025 | ₹152 Cr |
| Mar 2026 | ₹169 Cr |
Net profit by year
| Mar 2017 | ₹14.00 Cr |
|---|---|
| Mar 2018 | ₹17.00 Cr |
| Mar 2019 | ₹20.00 Cr |
| Mar 2020 | ₹15.00 Cr |
| Mar 2021 | ₹16.00 Cr |
| Mar 2022 | ₹22.00 Cr |
| Mar 2023 | ₹25.00 Cr |
| Mar 2024 | ₹26.00 Cr |
| Mar 2025 | ₹32.00 Cr |
| Mar 2026 | ₹35.00 Cr |
Analyst Forecasts
Forecast For
Mar 27 consensus · Price
₹1,370.00 +49.8% vs Sep 26
Reported High Mean Low
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 29.18 | 38.29 | 35.66 | 38.84 | 32.54 | 41.22 | 36.89 | 41.05 | 35.53 | 45.56 | 43.02 | 44.63 | 35.51 |
| Expenses | 22.22 | 29.19 | 28.47 | 28.99 | 23.26 | 29.79 | 28.07 | 30.19 | 26.58 | 32.45 | 35.59 | 30.38 | 29.48 |
| Operating Profit | 6.96 | 9.1 | 7.19 | 9.85 | 9.28 | 11.43 | 8.82 | 10.86 | 8.95 | 13.11 | 7.43 | 14.25 | 6.03 |
| OPM % | 23.85% | 23.77% | 20.16% | 25.36% | 28.52% | 27.73% | 23.91% | 26.46% | 25.19% | 28.78% | 17.27% | 31.93% | 16.98% |
| Other Income | 1.04 | 1.1 | 1.35 | 1.19 | 1.41 | 1.85 | 1.58 | 1.88 | 2.06 | 2.08 | 1.82 | 0.4 | 1.51 |
| Interest | 0.07 | 0.07 | 0.07 | 0.06 | 0.11 | 0.12 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 |
| Depreciation | 0.5 | 0.59 | 0.63 | 0.62 | 0.52 | 0.64 | 0.78 | 0.79 | 0.72 | 0.74 | 0.83 | 0.81 | 0.64 |
| PBT | 7.43 | 9.54 | 7.84 | 10.36 | 10.06 | 12.52 | 9.51 | 11.84 | 10.18 | 14.34 | 8.3 | 13.71 | 6.77 |
| Tax % | 27.73% | 23.27% | 31.12% | 23.94% | 26.34% | 23.32% | 31.65% | 27.87% | 23.48% | 29.08% | 28.55% | 20.86% | 13% |
| Net Profit | 5.37 | 7.32 | 5.4 | 7.88 | 7.42 | 9.6 | 6.51 | 8.54 | 7.79 | 10.16 | 5.93 | 10.85 | 5.89 |
| EPS (₹) | 12.17 | 16.59 | 12.24 | 17.86 | 16.81 | 21.75 | 14.75 | 19.35 | 17.65 | 23.02 | 13.44 | 24.58 | 13.35 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 85 | 94 | 103 | 115 | 123 | 119 | 109 | 124 | 137 | 142 | 152 | 169 | 169 |
| Expenses | 70 | 77 | 84 | 91 | 98 | 99 | 89 | 97 | 106 | 109 | 111 | 125 | 128 |
| Operating Profit | 15 | 16 | 20 | 24 | 25 | 20 | 20 | 27 | 30 | 33 | 40 | 44 | 41 |
| OPM % | 18% | 18% | 19% | 21% | 20% | 17% | 18% | 22% | 22% | 23% | 27% | 26% | 24% |
| Other Income | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | 5 | 7 | 6 | 6 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| PBT | 14 | 17 | 20 | 25 | 27 | 21 | 22 | 30 | 33 | 35 | 44 | 47 | 43 |
| Tax % | 33% | 36% | 34% | 32% | 26% | 30% | 24% | 25% | 25% | 26% | 27% | 25% | — |
| Net Profit | 10 | 11 | 14 | 17 | 20 | 15 | 16 | 22 | 25 | 26 | 32 | 35 | 33 |
| EPS (₹) | 20.76 | 23.19 | 29.06 | 37.5 | 43.14 | 32.4 | 35.95 | 48.59 | 55.76 | 58.87 | 72.64 | 78.72 | 74.39 |
| Div. Payout % | 30% | 31% | 28% | 24% | 24% | 25% | 28% | 25% | 26% | 26% | 25% | 26% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 |
| Reserves | 29 | 36 | 50 | 57 | 73 | 75 | 94 | 113 | 118 | 141 | 167 | 193 |
| Borrowings | 7 | 5 | 6 | 0 | 7 | 3 | 5 | 7 | 3 | 0 | 4 | 2 |
| Other Liabilities | 21 | 12 | 16 | 16 | 18 | 21 | 17 | 18 | 16 | 19 | 19 | 26 |
| Total Liabilities | 61 | 58 | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
| Fixed Assets | 12 | 12 | 11 | 10 | 10 | 12 | 11 | 11 | 10 | 10 | 15 | 19 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 40 | 46 |
| Investments | 0 | 1 | 2 | 5 | 5 | 4 | 7 | 8 | 11 | 17 | 21 | 27 |
| Other Assets | 49 | 45 | 64 | 62 | 87 | 88 | 103 | 123 | 119 | 136 | 120 | 132 |
| Total Assets | 61 | 58 | 76 | 77 | 103 | 104 | 120 | 143 | 141 | 164 | 195 | 225 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 9 | 8 | 10 | 16 | 13 | 15 | 19 | 9 | 17 | 8 | 28 | 27 |
| Investing | 1 | 0 | −10 | 1 | −11 | −3 | −19 | −1 | 3 | −1 | −17 | −19 |
| Financing | 1 | −5 | 1 | −18 | −2 | −11 | −1 | −6 | −21 | −7 | −8 | −9 |
| Net Cash Flow | 11 | 2 | 1 | −1 | 0 | 1 | 0 | 3 | −1 | 0 | 3 | −2 |
| Free Cash Flow | 8 | 5 | 10 | 16 | 11 | 11 | 18 | 7 | 15 | 6 | 8 | 13 |
| CFO/OP | 88 | 82 | 85 | 103 | 80 | 104 | 127 | 62 | 83 | 49 | 102 | 88 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 23 | 32 | 40 | 68 | 55 | 47 | 45 | 45 | 50 | 50 | 53 |
| Inventory Days | 107 | 109 | 128 | 73 | 99 | 120 | 92 | 115 | 92 | 103 | 109 | 154 |
| Days Payable | 54 | 44 | 72 | 44 | 66 | 58 | 56 | 83 | 67 | 75 | 100 | 91 |
| Cash Conversion Cycle | 85 | 88 | 89 | 69 | 101 | 117 | 83 | 77 | 70 | 78 | 59 | 115 |
| Working Capital Days | −11 | 6 | 10 | 25 | 35 | 32 | 17 | 16 | 31 | 36 | 31 | 41 |
| ROCE % | 42% | 40% | 39% | 42% | 37% | 26% | 24% | 26% | 27% | 26% | 27% | 27% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Jenburkt Pharmaceuticals insights
65 extracted metrics across FY10–FY27.
Documents
- 27 Aug 2014
- General announcements 12 Oct 2026
Frequently Asked Questions about Jenburkt Pharmaceuticals
What does Jenburkt Pharmaceuticals Ltd do?
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products
Where is Jenburkt Pharmaceuticals Ltd (JENBURPH) listed?
Jenburkt Pharmaceuticals Ltd trades as JENBURPH on the NSE and under code 524731 on the BSE.
Which sector does Jenburkt Pharmaceuticals Ltd belong to?
Jenburkt Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd trades at a PE ratio of 12.59 as of 4 Nov 2026, on earnings per share of ₹74.39, against a book value of ₹446.47 per share.
What is the 52-week high and low of Jenburkt Pharmaceuticals Ltd?
Over the last 52 weeks Jenburkt Pharmaceuticals Ltd has traded between ₹845 and ₹1,317 as of 4 Nov 2026.
Does Jenburkt Pharmaceuticals Ltd pay dividends?
Jenburkt Pharmaceuticals Ltd has a dividend yield of 2.32%.
What is the Return on Equity (ROE) of Jenburkt Pharmaceuticals Ltd?
Jenburkt Pharmaceuticals Ltd reported a return on equity of 20.20%. Its debt-to-equity ratio is 0.01.
Company Information
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524731.md for Jenburkt Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.